BURLINGTON, Mass., Feb. 23, 2012 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that Tom Sebok will be leading the company's advertising segment as the new President of inVentiv Health Communications. Sebok brings decades of communications expertise to inVentiv clients seeking to reach and motivate healthcare professionals and consumers.
Sebok's hiring coincides with inVentiv's realignment of communications services into functional groups, with one concentrating on advertising and paid media and the other focused on public relations and medical education. In his new role, Sebok will oversee GSW Worldwide, Ignite Health, The Navicor Group, Addison Whitney, Palio, Patient Marketing Group and inServ. He will be based in New York and report to Paul Meister, CEO of inVentiv Health, Inc.
"No other organization has such a breadth of healthcare experience and few can match the depth of inVentiv Health Communications talent," Meister said. "Tom's experience deepens our ability to help advertising clients reach and motivate consumers and professionals in the healthcare field. We are delighted that he is joining us."
The public relations group within inVentiv will continue to be led by Bob Chandler, President and CEO of Chandler Chicco Companies, who also will oversee the inVentiv Medical Education Group (iMEG) and report to Meister. "We see many opportunities for collaboration between PR and medical education on behalf of our clients, particularly as we expand this business globally," Meister said. "Working in close collaboration, Tom and Bob will lead teams offering the best services to a market demanding multi-specialty solutions."
Sebok previously served as President and CEO of Young & Rubicam's flagship New York agency, providing integrated marketing communications solutions for clients such as the Arthritis Foundation, Bayer Women's Health, Campbell's, Colgate-Palmolive, Chevron, Dell, Goldman Sachs, Hilton, J&J, Land Rover, LG, Mattel, Microsoft, Pfizer, USOC, Virgin Atlantic and Xerox. Prior to Y&R, Tom spent the bulk of his career at BBDO where he led that agency's global service of clients such as Bayer Consumer Care, Campbell's, FedEx, Frito-Lay, Lowe's, Motorola, PepsiCo and Pizza Hut. As Managing Director of BBDO New York, Tom was a key leader in BBDO's reinvention as an agency that excels in both traditional and new media. Earlier in his career he worked at Grey Advertising on the Beecham Products consumer business (now SKB) and Boehringer Ingelheim.
About inVentiv Health Communications
inVentiv Health Communications (iHC) is a full-spectrum, healthcare specialist agency dedicated to delivering exceptional multi-channel and multinational marketing programs. iHC provides relevant, flexible and cost-effective marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, enabling clients to succeed in a rapidly changing environment.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of the acquisition anticipated by this release and any future announced acquisitions, and any additional leverage we may incur in connection with the financing thereof, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers or swap counterparties; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self-insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; and the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Readers of this notice are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these and other factors.
SOURCE inVentiv Health, Inc.